Life Technologies Extends Partnership with DNAVEC
News Oct 21, 2013
Life Technologies Corporation has extended its collaborative agreement with Japanese firm DNAVEC Corporation to launch CytoTune™-iPS 2.0 Sendai Reprogramming Kit, the next-generation research technology that enables the most efficient method to develop induced pluripotent stem (iPS) cells from human somatic cells. The newest kit doubles the number of colonies that can be produced and represents the latest in a series of products that are planned from the collaboration.
CytoTune™-iPS 2.0 Sendai Reprogramming Kit uses a benign RNA virus developed by DNAVEC to deliver the reprogramming factors and clears out of the cell after about five replication cycles. The technology helps overcome major hurdles associated with traditional reprogramming techniques, which are highly inefficient and can lead to unwanted genetic mutations since vectors must insert themselves in the host cell's DNA to deliver their payload.
By extending its collaborative research agreement with DNAVEC Corp., Life Technologies plans to build on the success it's forged through the broad adoption of the CytoTune™ technology. Under the agreement, DNAVEC will undertake early stage R&D to apply its Sendai virus technology to third- and fourth-generation tools for use within the reprogramming and stem-cell workflows.
"This technology will provide revolutionary new tools to cell engineering research worldwide," said Mamoru Hasegawa, Ph.D., President of DNAVEC. "We are excited about the initiation of a new collaborative development program with Life Technologies, which aims to develop new vectors and products."
Efficient development of iPS cells provides highly sought-after advantages for the basic and translational research fields. Scientists who test existing or novel drugs in the hopes of treating specific conditions can have faster access to patient-derived, physiologically accurate cells for disease modeling studies.
"This partnership enables both organizations to leverage their respective strengths," said Chris Armstrong, Ph.D., General Manager and Vice President of Primary and Stem Cell Systems at Life Technologies. "DNAVEC's deep expertise in Sendai virus technology to develop breakthrough solutions is complemented by Life Technologies' global distribution channels that can rapidly put these novel products in the hands of customers to accelerate research and the promise of stem cells."
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Scleroderma Study Offers New Hope For SufferersNews
An unusual autoimmune disease that causes skin and lung damage can be treated effectively by stem cell transplant, a new study found. The approach could represent the first new treatment to improve survival in patients with severe scleroderma in more than four decades.READ MORE
Comments | 0 ADD COMMENT
Precision Medicine & Biomarkers Leaders Summit: USA
May 07 - May 08, 2018